Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis

International Angiology

Volumn 17, Issue 3, 1998, Pages 135-145

  Kirchmaier, C M ^a   Wolf, H ^a   Schafer H ^a   Ehlers, B ^a   Breddin, H K ^a  

^a NONE

Author keywords

Heparin low molecular weight; Pulmonary embolism; Thrombophlebitis

Indexed keywords

ANTIVITAMIN K; CERTOPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; LUNG SCINTISCANNING; LUNG VENTILATION PERFUSION RATIO; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHLEBOGRAPHY; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SCORING SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION; FEMALE; FEMORAL VEIN; FOLLOW-UP STUDIES; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; ILIAC VEIN; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PHLEBOGRAPHY; POPLITEAL VEIN; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 0031755859     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Salzman EW, Devkin D, Shapiro RM, Rosenberg R. Management of heparin therapy: controlled prospective trial. N Engl J Med 1975;292:1046-50.
2. Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990;322: 1260-4.
3. Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH et al. Continuous intravenous heparin compared with intermittend subcutaneous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med 1986;315:1109-14.
4. Bratt G, Tornbohm E, Graqvist St, Aberg W, Lockner D. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemostas 1985;54:813-7.
5. Holm HA, Ly B, Handeland GF, Abildgaard U, Arnesen KE, Gottschalk P et al. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis 1986;(Suppl.)2:30-7.
6. Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study. Circulation 1989;80:935-40.
7. Bratt G, Aberg W, Johansson M, Tornebohm E, Granqvist St, Lockner D. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemostas 1990;64:506-10.
8. Handeland GF, Abildgaard U, Holm HA, Arnesen KE. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 1990;39:107-12.
9. Holmström MC, Granquist BS, Bratt G, Törnebohm E, Lockner D. Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg. Thrombos Res 1992;67:49-55.
10. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, Kher A, Aiach M et al. Adjusted versus fixed doses of the low-molecular weight heparin Fragmin in the treatment of deep vein thrombosis. Thromb Haemostas 1994;71:698-702.
11. Lindmarker P, Holmström M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemostas 1994;72:186-90.
12. Ninet J, Bachet PH, Prandoni P, Ruol A, Vigo M, Barret A et al. A randomized trial of subcutaneous low molecular weight heaprin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemostas 1991;65:251-6.
13. Prandoni P, Lensing AWA, Büller HR, Carta M, Cogo A, Vigo M et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. The Lancet 1992;339:441-5.
14. Lopaciuk S, Meissner AJ, Filipecki S, Zawilska K, Sowier J, Ciesielski L et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemostas 1992;68:14-8.
15. Janvier G, Winnock S, Dugrais G, Vallet A, Dardel E, Sense JM et al. Treatment of deep venous thrombosis with a very low molecular weight heparin fragment (CY 222). Haemostasis 1987;7:49-58.
16. Janvier G, Freyburger G, Winnock S, Dugrais G, Boisseau M, Boissieras P. An open trial of Enoxaparin in the treatment of deep vein thrombosis of the leg. Haemostasis 1991;21:161-68.
17. Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P et al. Subcutaneous low-molecular weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993;153:1541-6.
18. Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T et al. Low molecular weight heparin versus Warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemostas 1994;72:191-7.
19. Siegbahn A, Y-Hassan S, Boberg J, Bylund H, Neerstrand RS, Ostergaard P et al. Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin, a dose finding study with LMWH-novo. Thrombos Res 1989;55:767-78.
20. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG et al. Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-82.
21. Notarbartolo A, Salanitri G, Davi G, Averna M, Barbagallo C, Catalano I. Low molecular weight heparin in the short and long-term treatment of deep vein thrombosis in diabetic subjects. Med Praxis 1988;9:1-13.
22. Zanghi M, Marici V, Costanzo M, Astuto L, Salanitri G. Deep vein thrombosis of the legs: new therapy by means of low molecular weight heparins. J Int Med Res 1988;16:474-84.
23. Tedoldi A, Botticella F, Maloberti MR. Antithrombophilic effect of low molecular weight heparins in patients with deep vein thrombosis. Clin Trials and Meta-Analysis 1993;28:215-25.
24. Harenberg J, Huck K, Bratsch H, Stehle G, Dempfle CE, Mall K et al. Therapeutic application of subcutaneous low molecular weight heparin in acute venous thrombosis. Haemostasis 1990;20(Suppl. 1):205-19.
25. Levine M, Gent M, Hirsh J, Ledere J, Anderson D, Weitz J et al. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996;334: 677-81.
26. Koopman MMW, Prandoni P. Piovella F, Ockelford PA, Brandjes DPM, Van der Meer J et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home. N Engl J Med 1996;334:682-7.
27. The Columbus Investigators. Low molecular weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-62.
28. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. Brit Med J 1994;309:299-304.
29. Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular weight heparins. Arch Intern Med 1995;155:601-7.
30. Kirchmaier CM, Lindhoff E, Rübesam B. Regression of deep vein thrombosis by i.v. administration of low molecular weight heparin. Thromb Res 1994;73:337-48.
31. Harenberg J, Giese C, Demptle CE, Stehle G, Heene DL. Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers. Thromb Haemostasis 1989; 61:357-362.
32. Marder VS, Soulen RL, Atichartarkan V, Budzynski AZ, Parulekar S, Kim IR et al. Quantitative venographic assessment of deep venous thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977;89:1018-29.
33. Partsch H. Periphere Venendnickmessung (Phlebodynamometrie). In: Simon H, Schoop W, editors. Diagnostik in der Kardiologie und Angioloeie. Stuttgart, New York: Thieme, 1986:512-25.
34. The PIOPED Investigators: Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA 1990;263:2753-59.
35. Horn M, Vollandt R. Multiple Tests und Auswahlverfahren. Gustav Fischer Verl. Stuttgart, Jena, New York, 1995:9-21.
36. Pocock SJ. Clinical trials: a practical approach. John Wiley & Sons, New York 1983.
37. Huisman MV, Buller HR, Ten Cate JW, Van Royen EA, Vreeken J, Kersten MJ et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1989;95:498-502.
38. Monreal M, Ruiz J, Olazabal A, Arias A, Roca J. Deep venous thrombosis and the risk of pulmonary embolism: a systematic study. Chest 1992;102:677-81.
39. Martin F, Leroyer C, Oger E. Bressollette L, Andre N, Nonent M et al. Embolie pulmonaire et niveau de thrombose. Rev Mal Respir 1995;12:465-9.
40. Meyer G, Brenot F, Pacouret G, Simmonneau G, Juvin KG, Charbonnier B et al. Subcutaneous low-molecular-weight-heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute nonmassive pulmonary embolism: an open randomized pilot study. Thromb Haemost 1995;74:1432-35.
41. Simmoneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Laurent M et al. for the THÉSÉE study group. A comparison of low molecular weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997;337:663-9.
42. Widmer LK, Zemp E, Widmer MT, Schmitt HE, Duckert F, Ritz R, Marbel G. Late results in deep vein thrombosis of the lower extremity. Vasa 1985; 14:264-8.
43. Eichlisberger R, Frauchiger B, Widmer MT, Widmer LK, Jäger K. Spätfolgen der tiefen Venenthrombose: Ein 13-Jahres-Follow-up von 223 Patienten. VASA 1994;23:234-43.
44. Franzeck UK, Schalch I, Jäger KA, Schneider E, Grimm J, Bollinger A. Prospective 12-year follow-up study of clinical and hemodynamic sequelae after deep vein thrombosis in low risk patients (Zürich study). Circulation 1996; 93:74-9.
45. Thiele C, Theiss W, Kurfürst-Seebauer R. Langzeitergebnisse nach fibrinolytischer Behandlung tiefer Venenthrombosen im Becken-Bein-Bereich. VASA 1989;18:48-55